Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Isolated in-vivo lung perfusion for treatment of lung cancer

Reference number
Coordinator Xvivo Perfusion Aktiebolag
Funding from Vinnova SEK 343 000
Project duration December 2014 - August 2015
Status Completed

Purpose and goal

This pre-project aimed to evaluate the feasibility of treating lung cancer by isolating the lung in-situ and perfusing the isolated lung with very hight doses of chemotherapy. This is supposedly achieved by perfusing the isolated lung with STEEN Solution which functions as carrier for the high dose chemotherapy.

Results and expected effects

We anticipated that IVLP with STEEN Solution as perfusate would result in fewer procedural complications compared to existing treatment of lung cancer patients. Our pre-study showed that this is most likely feasible, but further testing needs to be performed to validate the concept before we perform study on patients.

Approach and implementation

The pre-study was performed in collaboration with two leading clinics in Europe, and results of the pre-study forms a basis for initiation of a full in-vivo study on human subjects.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2014-04758

Page statistics